Reduced Cardiovascular Morbi-mortality by Sildenafil in Patients With Arterial Claudication

• Status: Unknown status
• Trial end date: 2017-09-01
• Target enrollment: 0
• Participant gender: All

Summary

Sildenafil has shown potential effects both on vasodilator mechanisms and as an inhibitor of the NO/GMPc Pain activation. The investigators aim at estimating the benefit of sildenafil in term of morbi-mortality in patients with arterial claudication on a multicenter prospective double blind study.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital, Angers
• Treatments: Sildenafil Citrate

Criteria

Inclusion Criteria:

• ABI<0.90

• Vascular type claudication

• stable walking impairment for at least 3 months

• Optimal cardiovasc treatment (Anti-platelet, HMGCoA-Inh, ACE-Inh or AT2 inh)

• Age > 30 years

Exclusion Criteria:

• Refuse to participate

• Administrative protection

• Severe renal (clearance < 30 ml/min) or hepatic (Child-Pugh C) failure